close

NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 3 Results for HLP003 in Major Depressive Disorder, Meeting Primary and Key Secondary Endpoints

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

This article has been disseminated on behalf of Helus Pharma and may include paid advertising.

Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced positive topline results from APPROACH, its pivotal Phase 3 trial evaluating HLP003 (deuterated psilocin) as an adjunctive treatment for adults with major depressive disorder (“MDD”). The randomized, double-blind, placebo-controlled study enrolled 222 participants and achieved statistically significant improvements across its primary, key secondary and other secondary endpoints. At the primary six-week endpoint, HLP003 produced a 19.5-point reduction from baseline on the Montgomery-Asberg Depression Rating Scale (“MADRS”), compared with 11.9 points for placebo, representing a 7.6-point difference (p<0.0001). Significant improvements were observed as early as Day 2, with treatment benefits maintained through Week 12, when the placebo-adjusted difference was 7.0 points (p<0.0001).

HLP003 also demonstrated statistically significant improvements in response and remission rates, with 50.9% of treated participants achieving remission at Week 6 compared with 18.2% receiving placebo. The treatment was generally well tolerated, with most adverse events mild to moderate and transient, although three treatment-related serious adverse events were reported. No new safety signals were identified. APPROACH is the first of three studies in the company’s PARADIGM Phase 3 program, which also includes the ongoing EMBRACE pivotal trial and EXTEND long-term extension study. Helus Pharma expects to report topline results from EMBRACE in the fourth quarter of 2027 as it advances HLP003 toward potential regulatory approval and commercialization.

To view the full press release, visit https://ibn.fm/IloYS

About Helus Pharma

Helus Pharma(TM), the commercial operating name of Cybin Inc., founded in 2019 (the “Company”), is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs – novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.

With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The Company operates in Canada, the United States, the United Kingdom and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma(TM) is a trademark of Cybin Corp.

NOTE TO INVESTORS: The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  258.33
-8.33 (-3.12%)
AAPL  352.90
-3.37 (-0.94%)
AMD  506.35
-27.71 (-5.19%)
BAC  50.26
-0.77 (-1.50%)
GOOG  283.82
-8.70 (-2.97%)
META  626.68
-15.01 (-2.34%)
MSFT  522.41
-1.47 (-0.28%)
NVDA  157.08
-5.77 (-3.54%)
ORCL  119.57
-5.78 (-4.61%)
TSLA  378.59
-11.63 (-2.98%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Starting at /week.